Granulocytapheresis in the treatment of severe alcoholic hepatitis: a case series.
OBJECTIVE
The management of alcoholic hepatitis remains controversial. Anti-tumour necrosis factor treatments have been studied recently. We piloted the use of granulocytapheresis (GCAP) in the management of severe alcoholic hepatitis.


METHODS
GCAP was performed on six patients with severe alcoholic hepatitis. Their clinical and laboratory progress was reviewed retrospectively.


RESULTS
Six of the patients underwent at least one session of GCAP. Three of the patients had coexistent renal failure and five of the six patients were corticosteroid nonresponders. All patients tolerated the procedure. However, three of the patients died during their hospital admission within 4 days of GCAP treatment. These three patients suffered from torrential variceal haemorrhage, multiorgan failure and pneumonia, respectively. Two patients died 18 and 25 days after their GCAP treatment, both with multiorgan failure. The survivor was the sole corticosteroid responder of the group. There was a trend towards a fall in serum bilirubin level after GCAP, but this did not reach significance.


CONCLUSIONS
GCAP is tolerated in severe alcoholic hepatitis; however, we have no evidence of survival advantage with this treatment.
Morris
Judith M
JM
Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, UK.
Dickson
Sheila
S
Neilson
Margaret
M
Hodgins
Paul
P
Forrest
Ewan H
EH
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D001781:Blood Component Removal / Q000379:methods* / Q000401:mortality; D006098:Granulocytes; D006519:Hepatitis, Alcoholic / Q000401:mortality / Q000628:therapy*; D006801:Humans; D007958:Leukocyte Count; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D009102:Multiple Organ Failure / Q000401:mortality; D015996:Survival Rate; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones